Latest Antiandrogens Stories
A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.
- Seminal Research on Prostate Cancer Resistance Leads to Development of MDV3100, Novel Drug Candidate - SAN FRANCISCO, April 7 /PRNewswire-FirstCall/ -- Medivation, Inc.
Johns Hopkins scientists identify receptor type that makes cancer cells resistant to therapy, more aggressive
Hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, but U.S. researchers suggest why.
Ariad Pharmaceuticals has reported encouraging preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with the anti-androgen agent, bicalutamide, in models of prostate cancer.
Cougar Biotechnology, Inc.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with the anti-androgen agent, bicalutamide, in models of prostate cancer.
Ariad Pharmaceuticals, a developer of medicines to treat cancer, has announced the initiation of a Phase II clinical trial by Merck & Co to evaluate the safety and efficacy of oral deforolimus, Ariad's investigational mTOR inhibitor, in patients with advanced prostate cancer.
Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that results from an ongoing Phase II clinical trial of Cougar's investigational drug CB7630 (abiraterone acetate) were presented today at the Prostate Cancer Foundation Scientific Retreat.
By Marie Price A new law requiring women to undergo an ultrasound before getting an abortion has been challenged in a lawsuit filed in Oklahoma County District Court by the Center for Reproductive Rights on behalf of Nova Health Systems, which does business as Reproductive Services in Tulsa.
- Emitting flashes of light; glittering.